secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001680367-25-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q2 net loss narrows to $12.5M; IND submitted for SL-325 Phase 1, $103M private placement
--------------------------------------------------------------------------------

- Net loss of $12.5M ($0.24/sh) vs $21.6M ($0.42/sh) YoY; R&D costs fell to $8.7M from $19.2M.
- Cash $50.5M as of June 30; up to $103M from oversubscribed private placement led by OrbiMed to fund ops into 2029.
- Submitted IND for SL-325 (DR3 blocking antibody) in July 2025; clearance expected Q3 2025; first dosing in Phase 1 expected Q3 2025.
- Phase 1 trial in healthy volunteers to complete Q2 2026; funds expected to support operations into 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/0001680367-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/sttk-20250814.htm
  HTML page:      https://secwatch.observer/filing/0001680367-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer